A budget biotech you likely never heard about is setting a course for Wall Street with some modest ambitions
A low-profile biotech founded by an exec with some deep roots in California biotech has mapped out plans for a very modest-sounding IPO.
Monopar Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
